AU Patent

AU2021270745A1 — IL-2 fusion polypeptide compositions and methods of making and using the same

Assigned to Mural Oncology Inc · Expires 2022-12-15 · 3y expired

What this patent protects

Provided herein are compositions comprising polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Rα chain, and methods of making and using such compositions.

USPTO Abstract

Provided herein are compositions comprising polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Rα chain, and methods of making and using such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021270745A1
Jurisdiction
AU
Classification
—
Expires
2022-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Mural Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.